REGN News and Press, Regeneron Pharmaceuticals Inc. From 04/29/24

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA ® HD (aflibercept) Injection 8 mg. The presentations are part...

2024-04-28 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

2024-04-25 11:24:05 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie Q1 Preview: Skyrizi and Rinvoq’s...

2024-04-25 08:19:01 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment...

2024-04-24 13:34:34 ET Summary Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to ...

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® (cemiplimab-rwlc) 17 presentations to highlight Regener...

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation ...

2024-04-22 15:42:04 ET More on United States 10-Year Bond Yield: Wall Street Lunch: Bond Bulls In Hibernation Dollar Consolidates But Adjustment Is Not Over Wall Street Lunch: So Long Summer Of Rate Cuts Bond yields tick down as cash moves to safety following...